The physicians and staff of NTIDC conduct multiple clinical trials for the treatment and study of HIV-infected individuals. Currently, the Research Department is participating in Phases I, II, III & IV trials and is one of the most respected and sought-after clinical trial sites in the north Texas region, providing our HIV patients with access to the most cutting-edge experimental treatment options available. All trials are conducted at NTIDC Research Department located at 3409 Worth Street on the Baylor University Medical Center campus in the Worth Street Tower, Suite 710, Dallas, Texas.
The Research Department’s primary objectives are to provide multiple options for our patients and the community including; naive, treatment experienced and treatment salvage studies. NTIDC’s Research Department has participated in multiple trials for many antiretroviral drugs including Protease Inhibitors, NNRTI’s, NRTI’s, Integrase Inhibitors, and Entry Inhibitors. Our Research Department enables us to participate in intense 12-hour pharmacokinetic studies whose outcomes provide important dosing and safety information.
NTIDC, through its Research Department is collaborating with the Baylor Institute of Immunology Research (BIIR) to study a therapeutic vaccine for the treatment of HIV. We remain committed to our work with pharmaceutical companies on the development of new antiretroviral therapies, vaccine’s and the improvement of currently used ART’s.
Our research team provides patients with a full spectrum of care including social work referrals, pharmacy support, standard of care and protocol required procedures.
If you have any questions or want information on our current research studies, please contact Bryan King at firstname.lastname@example.org. Thank you